WATCHLONGEVITY

Saturday, June 20, 2026

Joi and Blokes dba Joi + Blokes - 728283 - 06/08/2026
Importance
55
Trust
70
Urgency
30
REGULATORY · PRIMARY SOURCE

Joi and Blokes dba Joi + Blokes - 728283 - 06/08/2026

The FDA warned Joi + Blokes, a Colorado company, for making false claims about compounded semaglutide and tirzepatide (copycat versions of Ozempic, Wegovy, and Mounjaro). The company's website falsely suggested these drugs were FDA-approved and that Joi + Blokes made them, when neither is true.

Analysis

FDA keeps cracking down on compounders making false claims about semaglutide and tirzepatide. Less compounding competition means more patients pay full price for Novo and Lilly brand-name drugs.

  • FDA issued warning letter MARCS-CMS 728283 to Joi + Blokes of Denver, CO on June 8, 2026
  • Joi + Blokes website falsely labeled products with its own name, implying it was the compounder when it was not
  • Website claimed compounded semaglutide was 'bioidentical with more expensive brands' like Ozempic and Wegovy
FDA Drug Approvals & Databases4d
Read